Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 16Lymphoid 14Gastrointestinal 7Thoracic 3Plasma cell 3Other solid neoplasm 3Head & Neck 2Genitourinary 2CNS 2Breast 2Sarcoma 1Myeloid 1Gynecologic 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1Advanced Breast Cancer 1

Interventions

Cyclophosphamide 89Capecitabine 88Trastuzumab 81Docetaxel 81Paclitaxel 65Epirubicin 57pyrotinib 55Tamoxifen 54Letrozole 53Fulvestrant 49Vinorelbine 43Carboplatin 43Doxorubicin 41Radiotherapy 33Anastrozole 32exemestane 31Neoadjuvant Therapy 29palbociclib 27Drug Therapy 27Fluorouracil 24Bevacizumab 24pertuzumab 23Cisplatin 23eribulin 22Exercise 21130-nm albumin-bound paclitaxel 21Goserelin 20Gemcitabine 20Chemotherapy, Adjuvant 19Albumin-Bound Paclitaxel 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Immunotherapy, Adoptive × Breast × Clear all
NCT06724835 2024-12-09

Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T)

Shenzhen Celconta Life Science Co., Ltd.

Phase 1 Unknown
18 enrolled
Breast

Advanced Breast Cancer

NCT04609215 2022-04-20

ImmunoBreast - A Phase Ib Study

Odense University Hospital

Phase 1/2 Unknown
20 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡